| Ytd | -66.61% | |
| 1y | -81.35% |
| Open | 0.31 | Prev Close | 0.31 | Low | 0.31 | High | 0.34 | Mkt Cap | 22.41M |
| Vol | 268.29K | Avg Vol | 862.11K | EPS | -0.90 | P/E | N/A | Forward P/E | -2.33 |
| Beta | 1.07 | Short Ratio | 9.02 | Inst. Own | 86.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 0.70 | 200-d Avg | 0.97 | 1yr Est | 12.14 |
TCRX News
HC Wainwright & Co. analyst Andres Y. Maldonado downgrades TScan Therapeutics (NASDAQ:TCRX) f
Wedbush analyst David Nierengarten downgrades TScan Therapeutics (NASDAQ:TCRX) from Outperform to
Gainers bioAffinity Technologies (NASDAQ:BIAF) stock moved upwards by 54.3% to $10.17 during Wednes
U.S. stocks rose mid-session, led by materials; factory orders beat estimates. Linkhome, Purple Biot
The strategic pivot focuses TScan's efforts on developing in vivo-engineered TCR-T therapies.
U.S. stocks edged higher, led by the Dow and materials. Ollie’s beat EPS estimates; biotech and AI s
Gainers BioVie (NASDAQ:BIVI) stock increased by 15.7% to $1.55 during Wednesday's after-market
On August 12, 2026, TScan Therapeutics, Inc. (the "Company") received notice from Amgen Inc.
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates TScan Therapeutics (NASDAQ:TCRX) w
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.23) per share which missed the ana
Wedbush analyst David Nierengarten reiterates TScan Therapeutics (NASDAQ:TCRX) with a Outperform
TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the develo
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeu
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.22) per share which missed the ana
Wedbush analyst David Nierengarten maintains TScan Therapeutics (NASDAQ:TCRX) with a Outperform a
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.18) per share which beat the analy
Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercia
TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the develo
HC Wainwright & Co. analyst Andres Y. Maldonado maintains TScan Therapeutics (NASDAQ:TCRX) wi
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.28) per share which beat the analy
Needham analyst Gil Blum maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the pri
TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the develo
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.28) per share which met the analys
HC Wainwright & Co. analyst Andres Maldonado maintains TScan Therapeutics (NASDAQ:TCRX) with
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.26) per share which beat the analy
Needham analyst Gil Blum reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $9
Barclays analyst Peter Lawson maintains TScan Therapeutics (NASDAQ:TCRX) with a Overweight and lo
HC Wainwright & Co. analyst Andrew Fein reiterates TScan Therapeutics (NASDAQ:TCRX) with a Bu
Needham analyst Gil Blum maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the pri
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.30) per share which missed the ana
TScan Therapeutics' stock rises after announcing a $30 million financing deal with Lynx1, extend
ZCAR: 193% | Zoomcar Reports 43% Booking Surge, Revamps Website Ahead of Holiday Rush ADD: 161% | Co
HC Wainwright & Co. analyst Andrew Fein reiterates TScan Therapeutics (NASDAQ:TCRX) with a Bu
Needham analyst Gil Blum reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $11